Scholar Rock Holding (SRRK) Aktienübersicht
Die Scholar Rock Holding Corporation, ein biopharmazeutisches Unternehmen, konzentriert sich auf die Verbesserung des Lebens von Kindern und Erwachsenen mit spinaler Muskelatrophie (SMA) und anderen seltenen, schweren und schwächenden neuromuskulären Krankheiten. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 4/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
SRRK Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Scholar Rock Holding Corporation Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$54.88 |
| 52-Wochen-Hoch | US$56.54 |
| 52-Wochen-Tief | US$27.07 |
| Beta | 0.68 |
| 1 Monat Veränderung | 23.88% |
| 3 Monate Veränderung | 9.98% |
| 1 Jahr Veränderung | 54.68% |
| 3 Jahre Veränderung | 646.67% |
| 5 Jahre Veränderung | 86.48% |
| Veränderung seit IPO | 254.06% |
Aktuelle Nachrichten und Updates
SRRK: Regulatory Resubmission And Trial Updates Will Shape Balanced Risk Profile
Scholar Rock Holding's analyst price target has moved higher to $59.31 from $55.07, with analysts pointing to updated assumptions on fair value, profit margin and future P/E as key drivers of the change. Analyst Commentary Recent Street research on Scholar Rock Holding centers on updated price targets and reactions to regulatory milestones, giving you a clearer sense of how analysts are framing valuation, execution risk and potential growth corridors for the company.Scholar Rock: New Treatment Boost For SMA Patients -- With September PDUFA
Summary Scholar Rock Holding Corporation (SRRK) focuses on Apitegromab, a selective anti-latent myostatin antibody for Spinal Muscular Atrophy in patients aged 2 and above. The initial FDA BLA submission for Apitegromab was rejected, but SRRK has since resubmitted its BLA for review. The investment thesis centers on regulatory progress and the clinical potential of Apitegromab in addressing unmet needs in SMA. SRRK's future hinges on successful FDA approval and market adoption of its lead therapy. Read the full article on Seeking AlphaScholar Rock Holding (SRRK) Stock Could Be 14.1% Undervalued On Its SMA Narrative
Scholar Rock Holding (SRRK) stock has drawn investor attention after a recent move in its share price, with the company’s Nasdaq listing closing at $47.33 and showing mixed short and longer term return figures. See our latest analysis for Scholar Rock Holding. For context, Scholar Rock Holding’s recent 1-day share price return of 0.81% and 7-day share price return of 7.13% sit alongside a slightly weaker 30-day share price return, while its 1-year and 3-year total shareholder returns point to...Recent updates
SRRK: Regulatory Resubmission And Trial Updates Will Shape Balanced Risk Profile
Scholar Rock Holding's analyst price target has moved higher to $59.31 from $55.07, with analysts pointing to updated assumptions on fair value, profit margin and future P/E as key drivers of the change. Analyst Commentary Recent Street research on Scholar Rock Holding centers on updated price targets and reactions to regulatory milestones, giving you a clearer sense of how analysts are framing valuation, execution risk and potential growth corridors for the company.Scholar Rock: New Treatment Boost For SMA Patients -- With September PDUFA
Summary Scholar Rock Holding Corporation (SRRK) focuses on Apitegromab, a selective anti-latent myostatin antibody for Spinal Muscular Atrophy in patients aged 2 and above. The initial FDA BLA submission for Apitegromab was rejected, but SRRK has since resubmitted its BLA for review. The investment thesis centers on regulatory progress and the clinical potential of Apitegromab in addressing unmet needs in SMA. SRRK's future hinges on successful FDA approval and market adoption of its lead therapy. Read the full article on Seeking AlphaScholar Rock Holding (SRRK) Stock Could Be 14.1% Undervalued On Its SMA Narrative
Scholar Rock Holding (SRRK) stock has drawn investor attention after a recent move in its share price, with the company’s Nasdaq listing closing at $47.33 and showing mixed short and longer term return figures. See our latest analysis for Scholar Rock Holding. For context, Scholar Rock Holding’s recent 1-day share price return of 0.81% and 7-day share price return of 7.13% sit alongside a slightly weaker 30-day share price return, while its 1-year and 3-year total shareholder returns point to...Muscle-Targeted SMA Therapies And Global Expansion Will Reshape Long-Term Outlook
Catalysts About Scholar Rock Holding Scholar Rock Holding focuses on developing muscle-targeted therapies for rare and severe neuromuscular diseases, led by its apitegromab program for spinal muscular atrophy and a broader anti myostatin pipeline. What are the underlying business or industry changes driving this perspective?Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade
Summary Scholar Rock Holding Corporation's lead candidate, apitegromab, has shown promising efficacy in treating SMA and is awaiting FDA and EMA approval, with a potential market launch by late 2025. Apitegromab could achieve blockbuster status with peak revenue potential >$2.5bn, especially based on its ability to build muscle mass in combo with gene therapies like Spinraza and Zolgensma. Scholar Rock's obesity therapy potential with apitegromab and GLP-1 RA combo presents a high-risk, high-reward scenario, with significant upside if Phase 2 data is positive. Despite financial challenges and potential dilution, I upgrade SRRK stock to a "Buy" due to its promising pipeline and undervalued stock price at $30. Read the full article on Seeking AlphaScholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
Summary Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Apitegromab is being explored in the phase 2 proof-of-concept EMBRAZE study, given alongside GLP-1 drugs to treat patients with obesity; Data from this trial is expected in Q2 of 2025. Positive data from the phase 2 EMBRAZE study would lead to IND of SRK-439 in Q3 of 2025 to target obesity and other cardiometabolic disorders. The global obesity drugs market is expected to reach $200 billion by 2031. Read the full article on Seeking AlphaScholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, But Price Too High
Summary Scholar Rock's lead candidate, apitegromab, showed promising Phase 3 results in SMA, boosting shares by over 325%, with plans for regulatory submissions in the US and EU. Despite positive data, Scholar Rock faces financial challenges, including significant net losses and limited cash, suggesting potential future fundraisings. The company is exploring apitegromab's potential in obesity treatment, with a Phase 2 study underway, in combo with a GLP-1 agonist drug - results are expected in Q2 2025. Given current valuation and financial risks, I recommend a "Hold" rating, with potential buying opportunities post-approval or pre-obesity study results if the share price dips below $30, I'd suggest. Read the full article on Seeking AlphaScholar Rock: SMA Program Strides Forward With Positive Clinical Data
Summary Apitegromab met the primary endpoint in its phase 3 SAPPHIRE study for spinal muscular atrophy, setting up BLA & MAA filings in Q1 2025. Apitegromab is the first treatment targeting muscle fiber atrophy in SMA, potentially changing the standard of care and offering a competitive edge. Scholar Rock also has apitegromab being explored in a phase 2 study for obesity, with clinical data expected in Q2 2025, presenting another catalyst. The spinal muscular atrophy market in the 7 major markets [7MM] is expected to reach $13 billion by 2034. Read the full article on Seeking AlphaScholar Rock: Solid Data And Good Prospects
Summary Scholar Rock's stock price has increased from $6 to $16, indicating increased market interest. Scholar Rock develops apitegromab, a targeted therapy for Spinal Muscular Atrophy (SMA) that inhibits myostatin activation. Phase 2 data shows sustained improvement in motor function for non-ambulatory SMA patients receiving apitegromab. Phase 3 data expected in 4Q 2024. Read the full article on Seeking AlphaAktionärsrenditen
| SRRK | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -0.1% | 4.1% | 1.6% |
| 1Y | 54.7% | 41.1% | 18.6% |
Rendite im Vergleich zur Industrie: SRRK übertraf die Branche US Biotechs , die im vergangenen Jahr eine Rendite von 41.1 erzielte.
Rendite vs. Markt: SRRK übertraf den Markt US, der im vergangenen Jahr eine Rendite von 18.6 erzielte.
Preisvolatilität
| SRRK volatility | |
|---|---|
| SRRK Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: SRRK hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: SRRKDie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2012 | 289 | David Hallal | www.scholarrock.com |
Die Scholar Rock Holding Corporation, ein biopharmazeutisches Unternehmen, konzentriert sich auf die Verbesserung des Lebens von Kindern und Erwachsenen mit spinaler Muskelatrophie (SMA) und anderen seltenen, schweren und schwächenden neuromuskulären Krankheiten. Das neuartige Verständnis der molekularen Mechanismen der Wachstumsfaktor-Aktivierung innerhalb der Transforming Growth Factor Beta (TGFß)-Superfamilie hat die Entwicklung einer firmeneigenen Plattform ermöglicht. Diese Plattform wird für die Entwicklung von monoklonalen Antikörpern verwendet, die lokal und selektiv auf die Vorläufer oder latenten Formen von Wachstumsfaktoren abzielen.
Scholar Rock Holding Corporation's Grundlagenzusammenfassung
| SRRK grundlegende Statistiken | |
|---|---|
| Marktanteil | US$6.58b |
| Gewinn(TTM) | -US$408.73m |
| Umsatz(TTM) | n/a |
Ist SRRK zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| SRRK Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$0 |
| Kosten der Einnahmen | US$211.58m |
| Bruttogewinn | -US$211.58m |
| Sonstige Ausgaben | US$197.15m |
| Gewinn | -US$408.73m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -3.41 |
| Bruttomarge | 0.00% |
| Nettogewinnspanne | 0.00% |
| Schulden/Eigenkapital-Verhältnis | 71.2% |
Wie hat sich SRRK auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/06 20:23 |
| Aktienkurs zum Tagesende | 2026/07/02 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Scholar Rock Holding Corporation wird von 24 Analysten beobachtet. 16 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Madhu Kumar | Baird |
| Etzer Darout | Barclays |
| Evan Seigerman | BMO Capital Markets Equity Research |